Angeles Wealth Management LLC Acquires Shares of 1,526 Repligen Co. (NASDAQ:RGEN)

Angeles Wealth Management LLC acquired a new stake in Repligen Co. (NASDAQ:RGEN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,526 shares of the biotechnology company’s stock, valued at approximately $220,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in RGEN. UMB Bank n.a. lifted its holdings in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the last quarter. Blue Trust Inc. raised its position in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the period. Resources Management Corp CT ADV acquired a new stake in shares of Repligen during the 3rd quarter worth about $37,000. Quarry LP grew its stake in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares during the last quarter. Finally, nVerses Capital LLC bought a new position in Repligen in the 3rd quarter valued at about $45,000. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RGEN has been the topic of several research reports. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research report on Friday, January 3rd. Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. TD Cowen started coverage on Repligen in a research note on Monday. They issued a “buy” rating and a $200.00 price objective on the stock. Finally, HC Wainwright lowered their price target on shares of Repligen from $240.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Six analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $186.00.

Repligen Stock Performance

Shares of RGEN opened at $153.86 on Tuesday. The firm’s fifty day simple moving average is $155.37 and its two-hundred day simple moving average is $148.93. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $211.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.62 billion, a P/E ratio of -415.83, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same quarter last year, the firm posted $0.23 earnings per share. The firm’s revenue was up 9.7% on a year-over-year basis. As a group, analysts predict that Repligen Co. will post 1.54 EPS for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.